Sulbactam-Durlobactam in CRAB Infection: A Real-World Cohort Study (SD-CRAB)
This is a Single-center Real-world Observational Cohort Study of Sulbactam-Durlobactam for Carbapenem-Resistant Acinetobacter Baumannii Infections: Effectiveness, Safety, and Exposure-Response Analysis
This is a multicenter real-world observational cohort study designed to evaluate the effectiveness and safety of sulbactam-durlobactam in patients with carbapenem-resistant Acinetobacter baumannii (CRAB) infections. Patients receiving sulbactam-durlobactam will be compared with those receiving other anti-CRAB regimens during the same period.
The primary outcomes are 28-day all-cause mortality and clinical failure. Secondary outcomes include microbiological clearance, recurrence, length of hospital and ICU stay, duration of mechanical ventilation, and adverse events.
To reduce confounding inherent in observational studies, propensity score methods, including matching and inverse probability weighting, will be applied. A nested therapeutic drug monitoring (TDM) sub-cohort will be established to explore the relationship between drug exposure and clinical outcomes.
調査の概要
状態
介入・治療
詳細な説明
This is a single-center real-world observational cohort study including hospitalized adult patients with carbapenem-resistant Acinetobacter baumannii (CRAB) infections. Patients will be classified into two groups based on treatment exposure: those receiving sulbactam-durlobactam and those receiving alternative anti-CRAB regimens during the same period.
The study aims to evaluate the effectiveness and safety of sulbactam-durlobactam in high-risk populations, including transplant recipients and critically ill patients. The primary outcomes are 28-day all-cause mortality and clinical failure. Secondary outcomes include microbiological clearance, recurrence, ICU length of stay, duration of mechanical ventilation, and treatment-related adverse events.
To minimize bias inherent in observational studies, propensity score matching, inverse probability of treatment weighting (IPTW), and multivariable regression models will be applied to adjust for baseline differences between groups. Landmark analysis will be conducted to address time-related biases.
A nested therapeutic drug monitoring (TDM) sub-cohort will be included. Plasma samples will be collected at predefined time points within a dosing interval, and drug concentrations will be measured using validated LC-MS/MS methods. Population pharmacokinetic modeling will be performed to estimate exposure parameters, including Cmin, Cmax, and AUC. The relationship between drug exposure and clinical outcomes, as well as PK/PD target attainment, will be further explored.
Subgroup analyses will be conducted according to infection status (confirmed infection vs. donor-derived colonization or infection).
研究の種類
入学 (推定)
連絡先と場所
研究場所
-
-
Sichuan
-
Chengdu、Sichuan、中国、610072
- 募集
- Sichuan Provincial People's Hospital
-
コンタクト：
- Lingai Pan, MD
- 電話番号：+86 17708130236
- メール：panlingai2004@163.com
-
-
参加基準
適格基準
就学可能な年齢
- 大人
- 高齢者
健康ボランティアの受け入れ
サンプリング方法
調査対象母集団
Hospitalized adult patients receiving anti-CRAB antimicrobial therapy in real-world clinical practice, including:
- patients with confirmed carbapenem-resistant Acinetobacter baumannii (CRAB) infection; or
- transplant recipients with donor-derived CRAB colonization or infection receiving early targeted therapy.
説明
Inclusion Criteria:
- Age ≥18 years.
Hospitalized patients receiving anti-CRAB antimicrobial therapy, including:
- patients with confirmed carbapenem-resistant Acinetobacter baumannii (CRAB) infection based on microbiological testing in combination with clinical evidence of infection; or
- transplant recipients with donor-derived CRAB colonization or infection who receive early targeted antimicrobial therapy.
- Treatment initiation time can be clearly determined.
- Availability of clinical outcome data.
Exclusion Criteria:
- Colonization without evidence of active infection.
- Missing key clinical data.
- Inability to determine treatment initiation time.
- Pregnancy or lactation.
- Patients considered unsuitable by investigators.
研究計画
研究はどのように設計されていますか？
デザインの詳細
コホートと介入
グループ/コホート |
介入・治療 |
|---|---|
|
Sulbactam-Durlobactam Group
Patients receiving sulbactam-durlobactam within 48 hours after treatment initiation.
|
Sulbactam-durlobactam administered according to routine clinical practice for the treatment of carbapenem-resistant Acinetobacter baumannii (CRAB) infection.
|
|
Non-Sulbactam-Durlobactam Group
Patients receiving alternative anti-CRAB regimens during the same period without sulbactam-durlobactam.
|
この研究は何を測定していますか？
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
28-day All-Cause Mortality
時間枠：Up to 28 days after initiation of anti-CRAB therapy
|
All-cause mortality occurring within 28 days after initiation of anti-CRAB therapy.
|
Up to 28 days after initiation of anti-CRAB therapy
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Clinical Failure
時間枠：Up to 28 days after initiation of anti-CRAB therapy
|
Clinical failure defined as lack of clinical improvement, need for escalation of antimicrobial therapy, or death.
|
Up to 28 days after initiation of anti-CRAB therapy
|
|
Length of ICU stay
時間枠：Up to 90 days after ICU admission
|
Duration of ICU stay measured from ICU admission to ICU discharge.
|
Up to 90 days after ICU admission
|
|
Time to clinical improvement
時間枠：Up to 28 days after initiation of anti-CRAB therapy
|
Time from initiation of anti-CRAB therapy to predefined clinical improvement.
|
Up to 28 days after initiation of anti-CRAB therapy
|
|
Microbiological eradication
時間枠：Up to 14 days after initiation of anti-CRAB therapy
|
Microbiological eradication confirmed by follow-up culture negativity.
|
Up to 14 days after initiation of anti-CRAB therapy
|
協力者と研究者
出版物と役立つリンク
一般刊行物
- Tacconelli E, Carrara E, Savoldi A, Harbarth S, Mendelson M, Monnet DL, Pulcini C, Kahlmeter G, Kluytmans J, Carmeli Y, Ouellette M, Outterson K, Patel J, Cavaleri M, Cox EM, Houchens CR, Grayson ML, Hansen P, Singh N, Theuretzbacher U, Magrini N; WHO Pathogens Priority List Working Group. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis. 2018 Mar;18(3):318-327. doi: 10.1016/S1473-3099(17)30753-3. Epub 2017 Dec 21.
- Kaye KS, Shorr AF, Wunderink RG, Du B, Poirier GE, Rana K, Miller A, Lewis D, O'Donnell J, Chen L, Reinhart H, Srinivasan S, Isaacs R, Altarac D. Efficacy and safety of sulbactam-durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii-calcoaceticus complex: a multicentre, randomised, active-controlled, phase 3, non-inferiority clinical trial (ATTACK). Lancet Infect Dis. 2023 Sep;23(9):1072-1084. doi: 10.1016/S1473-3099(23)00184-6. Epub 2023 May 11.
- Covvey JR, Guarascio AJ. Sulbactam-durlobactam for the treatment of Acinetobacter baumannii-calcoaceticus complex. Expert Rev Anti Infect Ther. 2024 Nov;22(11):925-934. doi: 10.1080/14787210.2024.2400703. Epub 2024 Sep 8.
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
キーワード
追加の関連 MeSH 用語
その他の研究ID番号
- 2026-055
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。